Source: Morning Brew
Pharmaceutical giants are now moving beyond AI as a research tool into genuine bet-the-company partnerships, signaling that AI-accelerated drug discovery has crossed from speculative to strategically essential. This deal represents a structural shift in how drugs get made—outsourcing the computational heavy lifting to specialized AI firms rather than building it in-house—which could reshape both the competitive dynamics of pharma and the venture economics of biotech startups. For Lilly, the real signal isn’t the headline number but the performance-based payment structure, which means they’re confident enough to stake $2.75 billion on AI producing drugs that actually make it through development and licensing.